Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRSNASDAQ:CELUNYSE:CYBNNASDAQ:PBYI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.43+0.4%$1.38$1.05▼$5.17$154.30M0.411.21 million shs518,206 shsCELUCelularity$2.05+4.8%$1.90$1.00▼$5.22$48.74M0.76337,224 shs113,407 shsCYBNCybin$8.97+7.0%$7.54$4.81▼$13.88$206.46M0.68272,191 shs1.00 million shsPBYIPuma Biotechnology$3.61+5.1%$3.28$2.22▼$4.13$178.92M1.29430,606 shs441,242 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-3.40%+2.16%-2.07%-4.05%+29.09%CELUCelularity+5.95%-2.49%-10.50%+13.95%-37.38%CYBNCybin+2.94%+13.23%+5.40%+41.96%+2,173.71%PBYIPuma Biotechnology+3.00%+2.39%+3.00%+17.06%+5.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRSAclaris Therapeutics2.5246 of 5 stars3.62.00.00.02.51.70.6CELUCelularity0.2193 of 5 stars0.01.00.00.02.21.70.0CYBNCybin2.6272 of 5 stars3.60.00.00.02.40.81.3PBYIPuma Biotechnology4.2654 of 5 stars3.52.00.00.02.64.23.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$9.71581.70% UpsideCELUCelularity 0.00N/AN/AN/ACYBNCybin 3.25Buy$86.00858.32% UpsidePBYIPuma Biotechnology 3.00Buy$7.0094.17% UpsideCurrent Analyst Ratings BreakdownLatest CELU, PBYI, CYBN, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/28/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$8.005/14/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.005/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025ACRSAclaris TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M8.24N/AN/A$1.44 per share0.99CELUCelularity$54.22M0.91N/AN/A$0.37 per share5.55CYBNCybinN/AN/AN/AN/A$10.83 per shareN/APBYIPuma Biotechnology$230.50M0.78$0.92 per share3.91$1.88 per share1.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)CELUCelularity-$57.89M-$2.65N/A∞N/A-106.77%-271.88%-42.82%7/28/2025 (Estimated)CYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/APBYIPuma Biotechnology$30.28M$0.774.689.49N/A16.37%49.35%18.25%7/30/2025 (Estimated)Latest CELU, PBYI, CYBN, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2024CELUCelularity-$1.50-$0.59+$0.91-$0.59$5.20 million$18.13 million5/6/2025Q1 2025ACRSAclaris Therapeutics-$0.19-$0.12+$0.07-$0.12$3.55 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACELUCelularityN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/APBYIPuma BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A5.065.06CELUCelularity4.070.380.28CYBNCybinN/A24.2424.24PBYIPuma Biotechnology0.111.531.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CELUCelularity19.02%CYBNCybin17.94%PBYIPuma Biotechnology61.29%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics6.40%CELUCelularity22.10%CYBNCybin15.00%PBYIPuma Biotechnology23.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.28 million101.35 millionOptionableCELUCelularity22023.95 million18.66 millionOptionableCYBNCybin5023.02 million17.96 millionNot OptionablePBYIPuma Biotechnology20049.63 million38.07 millionOptionableCELU, PBYI, CYBN, and ACRS HeadlinesRecent News About These CompaniesIs Puma Biotechnology (PBYI) Stock Undervalued Right Now?June 27, 2025 | zacks.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain - NasdaqJune 26, 2025 | nasdaq.comPuma Biotechnology: Updated Timelines And A Resurgence In SentimentJune 25, 2025 | seekingalpha.comFast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a BargainJune 24, 2025 | zacks.comPuma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above Two Hundred Day Moving Average - Should You Sell?June 24, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 8,100 Shares of StockJune 18, 2025 | insidertrades.comBrian M. Stuglik Sells 8,100 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comInsider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 10,800 Shares of StockJune 17, 2025 | marketbeat.comPuma Biotechnology, Inc. (NASDAQ:PBYI) Director Allison Dorval Sells 11,610 SharesJune 17, 2025 | marketbeat.comAlessandra Cesano Sells 12,150 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comJay M. Moyes Sells 22,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comAdrian Senderowicz Sells 27,000 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) StockJune 17, 2025 | marketbeat.comShould Value Investors Buy Puma Biotechnology (PBYI) Stock?June 11, 2025 | zacks.comWith 57% ownership, Puma Biotechnology, Inc. (NASDAQ:PBYI) boasts of strong institutional backingJune 10, 2025 | finance.yahoo.comTwo Sigma Investments LP Purchases 131,916 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)June 9, 2025 | marketbeat.com78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial CorpJune 6, 2025 | marketbeat.comPuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 4, 2025 | businesswire.comWhy Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value InvestorsMay 28, 2025 | zacks.comAre Investors Undervaluing Puma Biotechnology (PBYI) Right Now?May 26, 2025 | zacks.comPuma Biotechnology's (NASDAQ:PBYI) Earnings Are Of Questionable QualityMay 15, 2025 | uk.finance.yahoo.comDespite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain StockMay 12, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCELU, PBYI, CYBN, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.42 +0.01 (+0.35%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Celularity NASDAQ:CELU$2.05 +0.09 (+4.80%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.Cybin NYSE:CYBN$8.97 +0.58 (+6.96%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.Puma Biotechnology NASDAQ:PBYI$3.60 +0.18 (+5.10%) As of 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
